en · de · es
cardarine-notes.peptides8425.com › News › Background And Regulatory Status — Research Overview

Background And Regulatory Status — Research Overview

By Editorial Desk · published 2026-01-03 · last reviewed 2026-01-19 · News

The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-01-19 and is reviewed periodically as new material appears.

Background and Regulatory Status

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

Cardarine at a glance

PropertyValueNotes
IUPAC name{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acidSystematic name for GW501516
CAS Registry Number317318-70-0Unique identifier for the parent compound
Molecular formulaC21H18F3NO3S2Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur
Molecular weight453.5 g/molApproximate value for the neutral form
AppearanceWhite to off-white powderTypical description for purified laboratory material

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Related pages on this site

Detection, Regulation, and Quality Context

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Further detail

=== Narcolepsy === While MCH does promote sleep, there has been no research that links MCH to narcolepsy. Research has instead found that in individuals with narcolepsy there is a decrease in orexin neurons, which would promote wakefulness, while the number of MCH neurons do not vary from the average non-narcoleptic individual.

is already present, morph A would outcompete morph B. Benzamide illustrates this process. Justus von Liebig and Friedrich Wöhler observed that when a boiling water solution of benzamide is cooled slowly, a metastable morph appears as a "white mass of silky needles". Later, a different crystal morph would appear within as small cavities, and expand into the entire mass after a few days.

It may be used diagnostically as a tumor marker for medullary thyroid cancer, in which high calcitonin levels may be present and elevated levels after surgery may indicate recurrence. It may even be used on biopsy samples from suspicious lesions (e.g., lymph nodes that are swollen) to establish whether they are metastases of the original cancer. Cutoffs for calcitonin to distinguish cases with medullary thyroid cancer have been suggested to be as follows, with a higher value increasing the suspicion of medullary thyroid cancer:

A mammal (from Latin mamma 'breast') is a vertebrate animal of the class Mammalia (). Mammals are characterized by the presence of milk-producing mammary glands for feeding their young, a broad neocortex region of the brain, fur or hair, and three middle ear bones. These characteristics distinguish them from reptiles and birds, from which their ancestors diverged in the Carboniferous period over 300 million years ago. Around 6,640 extant species of mammals have been described and divided into 27 orders. The study of mammals is called mammalogy. The largest orders of mammals, by number of species, are the rodents, bats, and eulipotyphlans (including hedgehogs, moles and shrews). The next three are the primates (including humans, monkeys and lemurs), the even-toed ungulates (including pigs, bovids and whales), and the Carnivora (including cats, dogs, and seals). Mammals are the only living members of Synapsida; this clade, together with Sauropsida (reptiles and birds), constitutes the larger Amniota clade. Early synapsids are referred to as "pelycosaurs." The more advanced therapsids became dominant during the Guadalupian. Mammals originated from cynodonts, an advanced group of therapsids, during the Late Triassic to Early Jurassic. Mammals achieved their modern diversity in the Paleogene and Neogene periods of the Cenozoic era, after the extinction of non-avian dinosaurs, and have been the dominant terrestrial animal group from 66 million years ago to the present.

== Disorders == When there are insufficient nutrient minerals or osteoblast dysfunction, the osteoid does not mineralize properly and accumulates. The resultant disorder is termed rickets in children and osteomalacia in adults. A deficiency of type I collagen, such as in osteogenesis imperfecta, also leads to defective osteoid and brittle, fracture-prone bones. In some cases, secondary hyperparathyroidism can cause a disturbance in mineralisation of calcium and phosphate. Another condition is a disturbance in primitive transformed cells of mesenchymal origin, which exhibit osteoblastic differentiation and produce malignant osteoid. This results in the formation of a malignant primary bone tumor known as osteosarcoma or osteogenic sarcoma. This malignancy most often develops in adolescence during periods of rapid osteoid formation (commonly referred to as growth spurts).

Sources: en.wikipedia.org

Background from the literature

In cellular biology, reticular connective tissue is a type of connective tissue with a network of reticular fibers, made of type III collagen (reticulum = net or network). Reticular fibers are not unique to reticular connective tissue, but only in this tissue type are they dominant. Reticular fibers are synthesized by special fibroblasts called reticular cells. The fibers are thin branching structures.

238U(22Ne,xn)260−xNo (x=4,5,6) This reaction was first studied in 1964 at FLNR. The team were able to detect decays from 252Fm and 250Fm. The 252Fm activity was associated with an ~8 s half-life and assigned to 256102 from the 4n channel, with a yield of 45 nb. They were also able to detect a 10 s spontaneous fission activity also tentatively assigned to 256102. Further work in 1966 on the reaction examined the detection of 250Fm decay using chemical separation and a parent activity with a half-life of ~50 s was reported and correctly assigned to 254102. They also detected a 10 s spontaneous fission activity tentatively assigned to 256102. The reaction was used in 1969 to study some initial chemistry of nobelium at the FLNR. They determined eka-ytterbium properties, consistent with nobelium as the heavier homologue. In 1970, they were able to study the SF properties of 256No. In 2002, Patin et al. reported the synthesis of 256No from the 4n channel but were unable to detect 257No. The cross section values for the 4-6n channels have also been studied at the FLNR.

=== Ootheca === Ootheca can be used as a distinguishing trait between the species of Eupolyphaga. E. sinensis ootheca are reddish brown in color with long arched serrations along one side, and compact ridges run longitudinal along the surface.

==== Reactions of cysteines ==== Because free cysteine rarely occurs on protein surface, it is an excellent choice for chemoselective modification. Under basic condition, the cysteine residues will be deprotonated to generate a thiolate nucleophile, which will react with soft electrophiles, such as maleimides and iodoacetamides (shown in the first two reactions in Figure 2 below). As a result, a carbon-sulfur bond is formed. Another modification of cysteine residues involves the formation of disulfide bond (shown in the third reaction in Figure 2). The reduced cysteine residues react with exogenous disulfides, generating new a disulfide bond on the protein. An excess of disulfides is often used to drive the reaction, such as 2-thiopyridone and 3-carboxy-4-nitrothiophenol. Electron-deficient alkynes were demonstrated to selectively react with cysteine residues of proteins in the presence of other nucleophilic amino acid residues. Depending on the alkyne substitution, these reactions can produce either cleavable (when alkynone derivatives are used), or hydrolytically stable bioconjugates (when 3-arylpropiolonitriles are used; the last reaction below in Figure 2).

Sources: en.wikipedia.org

Further detail

== Research == As of 2025, the department has 162 researchers, including 110 post-graduate researchers, 50 postdoctoral researchers and 49 research groups. Research spans four divisions including cellular and molecular pathology, immunology, microbiology and parasitology and virology.

== Research and pipeline == In 2025, Novo tested whether semaglutide helped slow progression for Alzheimer's disease. However, on November 24, 2025, the company announced that the studies failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or with dementia. Novo was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies. In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis. In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on "transformational biological and technological innovation".

Colyer continued his run of career best form into 2022 playing 18 games in a wing/half-forward role, and kicking multiple goals against GWS and Hawthorn, the latter of which he was arguably best on ground. Colyer signed a one-year contract extension at the end of the season. Colyer missed the first 5 games of the 2023 AFL season after a knee injury sustained during preseason saw him undergo surgery. However, he was not selected by Fremantle for the remainder of the season. Instead, he played for their WAFL affiliated side, Peel Thunder. He kicked two goals in the WAFL Grand Final against East Fremantle. In August, following the final game of Fremantle's season, Colyer along with teammate Nathan Wilson were informed that they would not be offered contracts in 2024, seemingly ending Colyer's football career after 14 years in the AFL.

In America, in 2009, further advanced counters were designed that included the ability to dispense hands-free – a feature that many operators had desired. This allowed pharmacies to automate their most commonly dispensed medications via calibrated cassettes. Thirty of a pharmacy's common medications would now be dispensed automatically. Another new model doubled that throughput via an enclosed robotic mechanism. Robotics had been employed in pharmacies since the mid-1990s, but later machines dispense and label filled patient vials in a comparatively tiny space (about nine square feet of floor space). These newer technologies allowed pharmacy staff to confidently dispense hundreds of prescriptions per day and still be able to manage the many functions of a busy community pharmacy. This would increase the number of patients that are able to be served each day.

At a practical level, a drug's bioavailability can be defined as the proportion of the drug that reaches the systemic circulation. From this perspective the intravenous administration of a drug provides the greatest possible bioavailability, and this method is considered to yield a bioavailability of 1 (or 100%). Bioavailability of other delivery methods is compared with that of intravenous injection (absolute bioavailability) or to a standard value related to other delivery methods in a particular study (relative bioavailability).

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Why is cardarine banned in sport?

It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.

What is the difference between cardarine and GW501516?

Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Network